Author

t. cardon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Assay:proteomics· 2 Approach:experimental assay· 1 Research Focus:protein folding & dynamics· 1 Approach:statistical model· 1

Frequent Co-Authors

I. Fournier· 2 shared M. Salzet· 2 shared M. Wisztorski· 2 shared S. Aboulouard· 2 shared A.-s. Lemaire· 1 shared C.-A. Maurage· 1 shared D. Bertin· 1 shared E. Le rhun· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

I. Fournier

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Overall patient's survival of glioblastoma associated to molecular markers: a pan-proteomic prospective study

L. Drelich, M. Duhamel, M. Wisztorski, S. Aboulouard, J.-p. Gimeno, P.-d. Caux, N. Ogrinc, P. Devos, T. Cardon, M. Weller, F. Escande, F. Zairi, C.-A. Maurage, I. Fournier, E. Le rhun, M. Salzet

This paper identifies three molecular groups of glioblastoma (GBM) associated with different survival outcomes using pan-proteomic analysis and validates prognostic markers for improved patient stratification.

bioRxiv · Nov 24, 2020 · PreprintCancer Biology

Preneoplastic lesions fimbria pan-proteomic studies establish the fimbriectomy benefit for BRCA1/2 patients and identify early diagnosis markers of HGSC

M. Wisztorski, P. saudemont, s. aboulouard, t. cardon, f. narducci, y.-m. robin, A.-s. Lemaire, D. Bertin, F. Kobeissy, E. Leblanc, I. Fournier, M. Salzet

The paper analyzes proteomic data from preneoplastic lesions in fallopian tubes to identify early diagnostic markers for HGSC and support fimbriectomy benefits for BRCA1/2 patients.

bioRxiv · Oct 4, 2020 · PreprintCancer Biology